Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.48 | N/A | +17.07% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.48 | N/A | +17.07% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings per share results, highlighting a focus on future growth. However, they did not provide specific revenue guidance.
We are pleased with our EPS performance this quarter.
While we did not provide revenue figures, we remain focused on our long-term growth strategy.
Zoetis reported a strong earnings per share, beating expectations by over 17%. However, the stock fell by 2.28% following the report, possibly due to the lack of revenue figures and forward guidance. Investors may be cautious about the company's future performance without clearer financial projections.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016